Treatment with biosimilar insulin glargine in clinical practice: case report
Authors:
Adriana Philippiová
Authors‘ workplace:
DIADA, s. r. o, Bardejov
Published in:
Diab Obez 2020; 20(39): 65
Category:
Case studies
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
-
All articles in this issue
- Editorial
- Comparison of the most recent guidelines for hyperglycemia management in patients with type 2 diabetes mellitus
- Concentrations of fT3 in child patients with obesity
- Non-alcoholic fatty liver disease from the point of view of diabetologist
- Diabetes mellitus and liver diseases
- The benefit of insulin glargine 300 U/ml for specific groups of patients in the context of available data
- Management of antidiabetic treatment in an elderly fragile patient with diabetes mellitus
- Peroral antidiabetics and thyroid diseases
- COVID-19: the topic of the day
- Comparison of cardiovascular studies with GLP-1 receptor agonists and their implication for clinical practice
- Therapy with SGLT2 inhibitors: case reports
- Treatment with the new modified insulin glargine (Semglee) in a patient with type 1 diabetes mellitus: case report
- A positive effect of intensification of the treatment with biosimilar insulin glargine on metabolic compensation: case report
- Treatment with biosimilar insulin glargine in clinical practice: case report
- Edukácia v diabetologickom edukačnom centre v Martine
- Diabetology EDUCATION FORUM
- Diabetes and obesity
- Journal archive
- Current issue
- About the journal
Most read in this issue
- Diabetes mellitus and liver diseases
- Treatment with the new modified insulin glargine (Semglee) in a patient with type 1 diabetes mellitus: case report
- Non-alcoholic fatty liver disease from the point of view of diabetologist
- Comparison of the most recent guidelines for hyperglycemia management in patients with type 2 diabetes mellitus